Rethinking the Dose-Response Relationship: Why Trazodone's Antidepressant Potential Is Often Undermined by Oversimplified Prescribing
Trazodone's FDA-approved antidepressant indication sits in a pharmacological blind spot for many clinicians, who associate the drug almost exclusively with low-dose sleep management. A closer look at the receptor-level mechanisms reveals why titrating too aggressively—or not thoughtfully enough—can paradoxically undermine the very antidepressant effect patients need. Understanding this tension is essential for optimizing outcomes in treatment-resistant and undertreated depression.